Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label study of fesoterodine in overactive bladder
2006-006070-22Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fesoterodine in overactive bladder (OAB), sponsored by Pfizer. Primary endpoints: Patient treatment satisfaction and Symptom relief. Started Jan 2007; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2006-006070-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006070-22.